
Abbott posts strong 2025 earnings, outlines 2026 growth plan and strategic moves
Abbott reported Q4 2025 GAAP EPS of $1.01 and adjusted EPS of $1.50 (up 12%), and full-year 2025 sales of $44.3B with adjusted EPS of $5.15 (up 10%). For 2026, it guides organic sales growth of 6.5%–7.5% and adjusted EPS of $5.55–$5.80 (about 10% at the midpoint). The company also plans to close its Exact Sciences acquisition in Q2 2026 to expand cancer diagnostics, announced regulatory advances in electrophysiology and ablation, and declared a quarterly dividend of $0.63.












